Compare EZPW & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZPW | KLRA |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 1996 | 2026 |
| Metric | EZPW | KLRA |
|---|---|---|
| Price | $32.46 | $14.14 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $30.67 | N/A |
| AVG Volume (30 Days) | ★ 974.7K | 745.2K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.09 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $747,954,000.00 | N/A |
| Revenue This Year | $25.40 | N/A |
| Revenue Next Year | $11.33 | N/A |
| P/E Ratio | $20.04 | ★ N/A |
| Revenue Growth | ★ 2.39 | N/A |
| 52 Week Low | $16.50 | $14.76 |
| 52 Week High | $37.13 | $23.82 |
| Indicator | EZPW | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | 35.61 |
| Support Level | $31.04 | N/A |
| Resistance Level | $36.56 | $19.02 |
| Average True Range (ATR) | 1.56 | 1.22 |
| MACD | 0.05 | -0.16 |
| Stochastic Oscillator | 53.28 | 7.03 |
EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buys and sells second-hand goods. The operating segments of the company are U.S. Pawn, Latin America Pawn, and Other Investments. The U.S. Pawn segment includes all pawn activities in the United States. The Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales, which are mainly collateral forfeited from pawn lending operations and used merchandise purchased from the customers.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.